CTP Newsroom - FDA
Stay up to date on the latest news and events from FDA's Center for Tobacco Products through the CTP Newsroom.
www.fda.govHere are the latest developments on tobacco plants from trusted sources:
-
US FDA updates on tobacco MRTP orders: The FDA renewed certain modified risk tobacco product orders for IQOS devices and HeatSticks, confirming that switching completely from cigarettes to IQOS can reduce exposure to harmful chemicals, while clarifying that this does not mean the products are safe or approved beyond those specific claims. This keeps the marketing claims tightly scoped and subject to ongoing review.
-
Psychedelic compounds produced by engineered tobacco plants: Reports indicate research where tobacco plants were bio-engineered to biosynthesize five psychedelic tryptamines (including psilocybin-related compounds). This represents a potential platform for research and production of certain therapeutics, though the work is early-stage and primarily exploratory.
-
Malawi and Zimbabwe tobacco sector signals: Coverage notes that Malawi faces a supply-demand imbalance in 2026, with production forecasts around 197,000 tons against demand near 170,000 tons, which could impact prices and revenue for growers; Zimbabwe’s season showed rising marketed volumes and improving farmer participation, with sales growth despite financing constraints. These dynamics influence global tobacco supply chains and pricing.
-
Regulatory and industry context: The FDA Center for Tobacco Products maintains ongoing communications about regulatory actions, research initiatives, and legal matters affecting tobacco products, including analytical testing guidance and import alerts. This broad regulatory activity shapes how tobacco products are marketed and studied in the near term.
If you’d like, I can pull more current articles on a particular angle (FDA regulatory updates, agricultural supply/demand, or scientific advances in engineered tobacco) and summarize with citations.